Exploring Potential Multi‐Target Inhibition Mechanisms of Ganoderma lucidum Against EBV‐Mediated DLBCL Using Integrative Bioinformatics, Machine Learning, and Network Pharmacology Approaches
Journal of Food Science · 2026-10 · 91 (10)
DOI: 10.1111/1750-3841.71575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Food Science, online erschienen am 19.10.2026. Verfasst von Azrin Ahmed und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Reishi, Epstein-Barr Virus Infections. Die Arbeit nennt 80 Literaturangaben.
Abstract (Originalsprache)
Epstein–Barr virus (EBV)‐associated diffuse large B‐cell lymphoma (DLBCL) represents a significant clinical challenge with limited targeted therapeutic options. Despite the known antiviral and anticancer properties of Ganoderma lucidum , its specific molecular mechanisms against EBV‐mediated DLBCL remain unexplored. Therefore, this study aimed to investigate the potential multi‐target inhibitory mechanisms of G. lucidum compounds against EBV‐associated DLBCL by integrating absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling of 1046 compounds; network pharmacology analysis for target identification; transcriptomic evaluation using DLBCL patient datasets from The Cancer Genome Atlas (TCGA) and Genotype‐Tissue Expression (GTEx) ( n = 47 tumors, n = 337 normals); molecular docking; density functional theory (DFT) calculations; machine learning–based activity prediction, molecular dynamics (MD) simulations; and Molecular Mechanics Poisson–Boltzmann Surface Area (MM–PBSA) binding free energy calculations. Eight compounds (kobusin, chrysin, dalbergin, galangin, isorhamnetin, lauric acid, piperbetol, and vitamin D3) demonstrated favorable ADMET profiles. Network pharmacology analysis identified 217 common targets, with AKT1 and BCL2 significantly upregulated in DLBCL tumors. Isorhamnetin showed the strongest AKT1 binding (−8.33 kcal/mol), surpassing control (−5.11 kcal/mol), whereas galangin exhibited the highest BCL2 affinity (−6.13 kcal/mol), outperforming control (−5.23 kcal/mol). Random forest achieved cross‐validation scores of 0.8634 ± 0.0158 for AKT1 and 0.8965 ± 0.0146 for BCL2, predicting IC 50
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
- Department of Bioscience and Biotechnology, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Sheikh Abdullah Al Ashik
Zitieren
APA
Ahmed, A., Kader, M. A., & Al Ashik, S. A. (2026). Exploring Potential Multi‐Target Inhibition Mechanisms of Ganoderma lucidum Against EBV‐Mediated DLBCL Using Integrative Bioinformatics, Machine Learning, and Network Pharmacology Approaches. Journal of Food Science, 91(10). https://doi.org/10.1111/1750-3841.71575
Vancouver
Ahmed A, Kader MA, Al Ashik SA. Exploring Potential Multi‐Target Inhibition Mechanisms of Ganoderma lucidum Against EBV‐Mediated DLBCL Using Integrative Bioinformatics, Machine Learning, and Network Pharmacology Approaches. Journal of Food Science. 2026;91(10). doi:10.1111/1750-3841.71575
BibTeX
@article{Ahmed2026,
author = {Ahmed, Azrin and Kader, Md Abdul and Al Ashik, Sheikh Abdullah},
title = {Exploring Potential Multi‐Target Inhibition Mechanisms of Ganoderma lucidum Against EBV‐Mediated DLBCL Using Integrative Bioinformatics, Machine Learning, and Network Pharmacology Approaches},
journal = {Journal of Food Science},
year = {2026},
volume = {91},
number = {10},
doi = {10.1111/1750-3841.71575}
}
EUVIMED